PURPOSE: Anti-CD19-directed chimeric antigen receptor (CAR) T-cell therapy has had a resounding effect on the treatment of chemotherapy-insensitive aggressive B-cell non-Hodgkin lymphoma (B-NHL). There are now two US Food and Drug Administration (FDA)-approved products available for treating these patients, and a third product is expected to be approved in the coming months. The question remains: Is there a preferred or best product for my patient? However, answering that question is more complicated than simply balancing the reported efficacy and toxicity results. DESIGN: This review outlines potential confounding factors involving the three products and their pivotal clinical trials and highlights additional considerations of manufacturing reliability and overall cost that must be considered when weighing one product against another. It will also review the directions in which the field is moving and strategies being examined to improve efficacy as well as toxicity. CONCLUSION: Because a randomized three-arm clinical trial is unlikely, a product may have to be chosen on the basis of results from treatment centers that have experience with all three products. But by the time those results are available, they are likely to be outdated because, given the rapid evolution of the field, the next product will probably have been identified.
PURPOSE: Anti-CD19-directed chimeric antigen receptor (CAR) T-cell therapy has had a resounding effect on the treatment of chemotherapy-insensitive aggressive B-cell non-Hodgkin lymphoma (B-NHL). There are now two US Food and Drug Administration (FDA)-approved products available for treating these patients, and a third product is expected to be approved in the coming months. The question remains: Is there a preferred or best product for my patient? However, answering that question is more complicated than simply balancing the reported efficacy and toxicity results. DESIGN: This review outlines potential confounding factors involving the three products and their pivotal clinical trials and highlights additional considerations of manufacturing reliability and overall cost that must be considered when weighing one product against another. It will also review the directions in which the field is moving and strategies being examined to improve efficacy as well as toxicity. CONCLUSION: Because a randomized three-arm clinical trial is unlikely, a product may have to be chosen on the basis of results from treatment centers that have experience with all three products. But by the time those results are available, they are likely to be outdated because, given the rapid evolution of the field, the next product will probably have been identified.
Authors: Lorenz Selberg; Peter Stadtherr; Sascha Dietrich; T Hien Tran; Thomas Luft; Ute Hegenbart; Andrea Bondong; Julia Meissner; Nora Liebers; Michael Schmitt; Anthony Dick Ho; Carsten Müller-Tidow; Peter Dreger Journal: Bone Marrow Transplant Date: 2020-06-18 Impact factor: 5.483
Authors: Peter Dreger; Timothy S Fenske; Silvia Montoto; Marcelo C Pasquini; Anna Sureda; Mehdi Hamadani Journal: Biol Blood Marrow Transplant Date: 2020-01-07 Impact factor: 5.742
Authors: Carmen Alvarez-Fernández; Laura Escribà-Garcia; A C Caballero; Eva Escudero-López; Cristina Ujaldón-Miró; Rosanna Montserrat-Torres; Paula Pujol-Fernández; Jorge Sierra; Javier Briones Journal: Clin Transl Immunology Date: 2021-04-29
Authors: Penny Q Fang; Jillian R Gunther; Susan Y Wu; Bouthaina S Dabaja; Loretta J Nastoupil; Sairah Ahmed; Sattva S Neelapu; Chelsea C Pinnix Journal: Front Oncol Date: 2021-03-25 Impact factor: 6.244
Authors: Eytan Herzig; Kaman Chan Kim; Thomas A Packard; Noam Vardi; Roland Schwarzer; Andrea Gramatica; Steven G Deeks; Steven R Williams; Kyle Landgraf; Nigel Killeen; David W Martin; Leor S Weinberger; Warner C Greene Journal: Cell Date: 2019-10-24 Impact factor: 41.582